Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Plasmodium falciparum | M18 aspartyl aminopeptidase | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | aspartyl aminopeptidase (M18 family) | 0.0087 | 0.2625 | 0.3054 |
Mycobacterium ulcerans | esterase/lipase LipP | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | aspartyl aminopeptidase | 0.0087 | 0.2625 | 0.3062 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 0.2625 | 0.3062 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 0.2625 | 0.3062 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0087 | 0.2625 | 0.2625 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.8593 | 1 |
Echinococcus granulosus | geminin | 0.0205 | 0.8593 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0204 | 0.8572 | 1 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0223 | 0.9506 | 1 |
Toxoplasma gondii | ABC1 family protein | 0.0035 | 0 | 0.5 |
Trypanosoma brucei | aspartyl aminopeptidase, putative | 0.0087 | 0.2625 | 1 |
Mycobacterium tuberculosis | Probable aminopeptidase PepC | 0.0087 | 0.2625 | 0.2761 |
Mycobacterium leprae | PROBABLE AMINOPEPTIDASE PEPC | 0.0087 | 0.2625 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 0.8593 | 1 |
Mycobacterium ulcerans | beta-lactamase | 0.0035 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 0.0293 | 0.0293 |
Trypanosoma cruzi | metallo-peptidase, Clan MH, Family M20 | 0.0087 | 0.2625 | 1 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0041 | 0.0293 | 0.0293 |
Trichomonas vaginalis | set domain proteins, putative | 0.0232 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0035 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 0.0293 | 0.0293 |
Echinococcus granulosus | aspartyl aminopeptidase | 0.0087 | 0.2625 | 0.3054 |
Leishmania major | aspartyl aminopeptidase, putative,metallo-peptidase, Clan MH, Family M20 | 0.0087 | 0.2625 | 1 |
Echinococcus multilocularis | aspartyl aminopeptidase | 0.0087 | 0.2625 | 0.3054 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.8593 | 1 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0041 | 0.0293 | 0.0293 |
Entamoeba histolytica | aminopeptidase, putative | 0.0087 | 0.2625 | 0.5 |
Entamoeba histolytica | aspartyl aminopeptidase, putative | 0.0087 | 0.2625 | 0.5 |
Plasmodium vivax | M18 aspartyl aminopeptidase, putative | 0.0087 | 0.2625 | 1 |
Mycobacterium ulcerans | fusion of enoyl-CoA hydratase, EchA21 and lipase, LipE | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | aspartyl aminopeptidase (M18 family) | 0.0087 | 0.2625 | 0.3054 |
Mycobacterium ulcerans | lipase LipD | 0.0035 | 0 | 0.5 |
Plasmodium falciparum | M18 aspartyl aminopeptidase | 0.0087 | 0.2625 | 0.5 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0041 | 0.0293 | 0.0293 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0087 | 0.2625 | 0.2625 |
Trichomonas vaginalis | hypothetical protein | 0.0041 | 0.0293 | 0.0293 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0087 | 0.2625 | 0.2625 |
Brugia malayi | Aspartyl aminopeptidase | 0.0087 | 0.2625 | 0.3062 |
Trypanosoma cruzi | aspartyl aminopeptidase, putative | 0.0087 | 0.2625 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0204 | 0.8572 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 0.0293 | 0.0293 |
Trypanosoma brucei | aspartyl aminopeptidase, putative | 0.0087 | 0.2625 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.93 um | PUBCHEM_BIOASSAY: QFRET-based biochemical high throughput dose response assay for inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP). (Class of assay: confirmatory) [Related PubChem assays: 2170 (Confirmation screen (PFM18AAP inhibitors).), 1855 (Summary AID.)] | ChEMBL. | No reference |
IC50 (binding) | > 59.642 um | PUBCHEM_BIOASSAY: QFRET-based counterscreen for inhibitors of PFM18AAP: biochemical high throughput dose response assay for inhibitors of the Cathepsin L proteinase (CTSL1). (Class of assay: confirmatory) [Related pubchem assays: 2178 (Confirmation screen (PFM18AAP inhibitors).), 1855 (Summary AID.)] | ChEMBL. | No reference |
Potency (functional) | 0.1636 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 25.1189 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.